Streetbeat News

LRMR

Larimar Therapeutics, Inc.

https://www.larimartx.com

Industry

Biotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

James Hardie Industries (NYSE:JHX) shares fell 14.3% after reporting worse-than-expected quarterly earnings and sales. JP Morgan downgraded the stock from Overweight to Neutral. Other notable movers include MGO Global (NASDAQ:MGOL) up 194% after Q1 results, and Greenwave Technology Solutions (NASDAQ:GWAV) down 60.5% after reporting a year-over-year decrease in Q1 results.

Portfolio Pulse from Avi Kapoor

May 21, 2024 | 5:36 pm

JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Larimar Therapeutics (NASDAQ:LRMR) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:37 pm

U.S. stocks were mostly higher on Tuesday, with notable gains from XPeng Inc. (NYSE:XPEV), Waldencast plc (NASDAQ:WALD), Larimar Therapeutics, Inc. (NASDAQ:LRMR), Nukkleus Inc. (NASDAQ:NUKK), Transcat, Inc. (NASDAQ:TRNS), Bloom Energy Corporation (NYSE:BE), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Mesoblast Limited (NASDAQ:MESO), Iris Energy Limited (NASDAQ:IREN), Nikola Corporation (NASDAQ:NKLA), Lotus Technology Inc. (NASDAQ:LOT), and Dollar General Corporation (NYSE:DG).

Portfolio Pulse from Avi Kapoor

May 21, 2024 | 2:38 pm

Shares of Larimar Therapeutics (NASDAQ:LRMR) surged 17.6% in pre-market trading after the FDA lifted a partial clinical hold on its nomlabofusp clinical program. Other notable pre-market movers include Edible Garden AG (NASDAQ:EDBL) up 94.5%, MGO Global (NASDAQ:MGOL) up 83.6%, and Meta Materials (NASDAQ:MMAT) up 59.1%. On the downside, Greenwave Technology Solutions (NASDAQ:GWAV) fell 59.2%, Rubicon Technologies (NYSE:RBT) dropped 24.1%, and Palo Alto Networks (NASDAQ:PANW) declined 7.9% despite better-than-expected earnings.

Portfolio Pulse from Avi Kapoor

May 21, 2024 | 12:12 pm

The article highlights the pre-market movements of 12 health care stocks on Tuesday. Notable gainers include Biodexa Pharmaceuticals (BDRX), Durect (DRRX), Larimar Therapeutics (LRMR), Tevogen Bio Holdings (TVGN), Envoy Medical (COCH), and Citius Pharma (CTXR). Significant losers include Scorpius Holdings (SCPX), Orgenesis (ORGS), SINTX Techs (SINT), Kazia Therapeutics (KZIA), NovaBay Pharmaceuticals (NBY), and Akanda (AKAN).

Portfolio Pulse from Benzinga Insights

May 21, 2024 | 12:06 pm

Larimar Therapeutics shares are trading higher after the company announced that the FDA removed the partial clinical hold previously placed on the nomlabofusp clinical program.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 10:33 am

Larimar Therapeutics shares are trading higher after the company announced that the FDA removed the partial clinical hold previously placed on the nomlabofusp clinical program.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 8:52 pm

The article highlights the performance of 12 health care stocks during Monday's after-market session. Larimar Therapeutics (LRMR) saw the highest gain with a 23.6% increase, while NovaBay Pharmaceuticals (NBY) experienced the largest decline, falling by 9.9%. The article also mentions earnings reports for several companies.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 8:31 pm

The FDA has removed the partial clinical hold on Larimar Therapeutics' Nomlabofusp program for Friedreich's Ataxia. This decision follows a review of Phase 2 study data. Larimar plans to escalate the dose in their ongoing study and aims to submit a Biologics License Application by the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 8:07 pm

Larimar Therapeutics reported having $239M in cash, cash equivalents, and marketable securities as of March 31, 2024, extending its projected cash runway into 2026. This financial position suggests a stable outlook for the company's operations and potential for continued development of its projects without immediate financial pressure.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:39 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.